In the latest session, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $5.71 down -1.89% from its previous closing price of $5.82. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 2152355 shares were traded.
Ratios:
For a deeper understanding of Amneal Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.36. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.91. In the meantime, Its Debt-to-Equity ratio is 8.48 whereas as Long-Term Debt/Eq ratio is at 8.11.
On March 08, 2021, Goldman Upgraded its rating to Buy which previously was Sell and also upped its target price recommendation from $4 to $6.50.
Guggenheim Upgraded its Neutral to Buy on December 14, 2020, while the target price for the stock was maintained at $5.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 when BOYER ANDREW S sold 29,302 shares for $4.13 per share. The transaction valued at 120,921 led to the insider holds 244,739 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 1.75B and an Enterprise Value of 4.47B. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 90.21, and their Forward P/E ratio for the next fiscal year is 9.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 2.66. Its current Enterprise Value per Revenue stands at 1.87 whereas that against EBITDA is 9.56.
Stock Price History:
Over the past 52 weeks, AMRX has reached a high of $6.30, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is 5.60, while the 200-Day Moving Average is calculated to be 4.09.
Shares Statistics:
For the past three months, AMRX has traded an average of 1.38M shares per day and 1.19M over the past ten days. A total of 151.49M shares are outstanding, with a floating share count of 110.04M. Insiders hold about 64.10% of the company’s shares, while institutions hold 24.79% stake in the company. Shares short for AMRX as of Jan 31, 2024 were 2.54M with a Short Ratio of 1.84, compared to 2.52M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.83% and a Short% of Float of 0.93%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.09 for the current quarter, with a high estimate of $0.15 and a low estimate of $0.07, while EPS last year was $0.23. The consensus estimate for the next quarter is $0.11, with high estimates of $0.17 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.66 and $0.57 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $0.6, with 5 analysts recommending between $0.64 and $0.55.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $634.23M this quarter.It ranges from a high estimate of $646.68M to a low estimate of $618.87M. As of the current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $609.76M, an estimated increase of 4.00% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $601.02M, an increase of 7.80% over than the figure of $4.00% in the same quarter last year. There is a high estimate of $619.84M for the next quarter, whereas the lowest estimate is $589.2M.
A total of 5 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $2.42B, while the lowest revenue estimate was $2.4B, resulting in an average revenue estimate of $2.41B. In the same quarter a year ago, actual revenue was $2.21B, up 9.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.58B in the next fiscal year. The high estimate is $2.65B and the low estimate is $2.51B. The average revenue growth estimate for next year is up 7.20% from the average revenue estimate for this year.
